Loading
Adding pembrolizumab to gemcitabine-cisplatin, with gemcitabine continued as maintenance, lengthened survival in advanced biliary tract cancer by about two months, confirming the role of chemo-immunotherapy shown by TOPAZ-1.
Phase 3 placebo-controlled trial of 1,069 patients with untreated metastatic or unresectable biliary tract cancer randomised to pembrolizumab or placebo with gemcitabine-cisplatin, with gemcitabine continued beyond eight cycles.
Median overall survival was 12.7 versus 10.9 months (hazard ratio 0.83), with a consistent effect across subgroups and no new safety signals.
Pembrolizumab with gemcitabine-cisplatin is an approved first-line option for advanced biliary tract cancer alongside durvalumab-based therapy.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gemcitabine, Cisplatin.
Shares KEYNOTE-966, Intrahepatic cholangiocarcinoma, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.
Shares Intrahepatic cholangiocarcinoma, Gemcitabine, Cisplatin, Pembrolizumab.
Shares Intrahepatic cholangiocarcinoma, Gemcitabine, Cisplatin, Pembrolizumab.
Shares Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gemcitabine, Cisplatin.
Shares Intrahepatic cholangiocarcinoma, Gemcitabine, Cisplatin.
Shares Intrahepatic cholangiocarcinoma, Gemcitabine, Cisplatin.
Shares Intrahepatic cholangiocarcinoma, Gemcitabine, Cisplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/